Pair Name	Artesunate, Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Gene Regulation	Down-regulation	Expression	NUS1	hsa116150
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
Result	We report that sorafenib treatment in combination with artesunate overcomes HCC resistance to sorafenib alone in a cell culture model.

Pair Name	Artesunate, Sorafenib
Disease Info	[ICD-11: XH50P3]	Non‑hodgkin lymphoma		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	GPX4	hsa2879
	Down-regulation	Expression	MCL1	hsa4170
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	PECAM1	hsa5175
	Down-regulation	Expression	STAT3	hsa6774
In Vitro Model	SU-DHL-4	Diffuse large B-cell lymphoma	Homo sapiens (Human)	CVCL_0539
Result	Artesunate synergistically promotes sorafenib‑induced apoptosis and ferroptosis in non‑Hodgkin lymphoma cells through inhibition of the STAT3 pathway

Pair Name	Artesunate, Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Mitochondria-dependent autophagy
Gene Regulation	Down-regulation	Expression	AFAP1L2	hsa84632
	Down-regulation	Phosphorylation	FUNDC1	hsa139341
	Up-regulation	Expression	MAP1LC3B	hsa81631
	Down-regulation	Phosphorylation	SRC	hsa6714
Result	Artesunate may be a promising strategy to mitigate sorafenib resistance in HCC via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy.